A. Vergnenègre

16.7k total citations
223 papers, 3.6k citations indexed

About

A. Vergnenègre is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, A. Vergnenègre has authored 223 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 152 papers in Pulmonary and Respiratory Medicine, 105 papers in Oncology and 25 papers in Surgery. Recurrent topics in A. Vergnenègre's work include Lung Cancer Treatments and Mutations (126 papers), Lung Cancer Diagnosis and Treatment (52 papers) and Lung Cancer Research Studies (45 papers). A. Vergnenègre is often cited by papers focused on Lung Cancer Treatments and Mutations (126 papers), Lung Cancer Diagnosis and Treatment (52 papers) and Lung Cancer Research Studies (45 papers). A. Vergnenègre collaborates with scholars based in France, Spain and Italy. A. Vergnenègre's co-authors include C. Chouaïd, M. Pérol, G. Robinet, H. Léna, P. Fournel, J. Le Treut, P. Thomas, H. Le Caer, I. Monnet and Nicolás Roche and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

A. Vergnenègre

209 papers receiving 3.4k citations

Peers

Countries citing papers authored by A. Vergnenègre

Since Specialization

Citations

This map shows the geographic impact of A. Vergnenègre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Vergnenègre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Vergnenègre more than expected).

Fields of papers citing papers by A. Vergnenègre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Vergnenègre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Vergnenègre. The network helps show where A. Vergnenègre may publish in the future.

Co-authorship network of co-authors of A. Vergnenègre

This figure shows the co-authorship network connecting the top 25 collaborators of A. Vergnenègre. A scholar is included among the top collaborators of A. Vergnenègre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Vergnenègre. A. Vergnenègre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo) 2023 ·Lung Cancer ·A. Vergnenègre, I. Monnet, Charles Ricordel, (unknown), (unknown), Massimo Bernardi, R. Corre, Florian Guisier, S. Hominal, G. Le Garff, Olivier Bylicki, Chrystèle Locher, Margaux Geier, C. Chouaïd, G. Robinet	5
2	Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study) 2021 ·Lung Cancer ·J.B. Auliac, I. Monnet, (unknown), Laurent Greillier, Margaux Geier, L. Falchero, G. Le Garff, R. Lamy, Florian Guisier, Charles Ricordel, C. Chouaïd, A. Vergnenègre	3
3	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC 2021 ·Journal of Thoracic Oncology ·Jacek Jassem, Filippo de Marinis, Giuseppe Giaccone, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Cristina Oprean, Young‐Chul Kim, Zoran Andrić, Simonetta Mocci, Ida Enquist, Kimberly M. Komatsubara, Mark L. McCleland, Hiroshi Kuriki, (unknown), See Phan, David R. Spigel, Roy S. Herbst	114
4	Endobronchials Valves: Impact of the 2 Step Approach on Pneumothorax Rates 2020 ·Thomas Egenod, (unknown), (unknown), A. Vergnenègre, B. Melloni, (unknown)	1
5	OA15.02 Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial 2019 ·Journal of Thoracic Oncology ·Nathalie Baize, I. Monnet, Laurent Greillier, Margaux Geier, H. Léna, Henri Janicot, A. Vergnenègre, Jacky Créquit, R. Lamy, J.B. Auliac, J. Le Treut, H. Le Caer, R. Gervais, Éric Dansin, A. Madroszyk, (unknown), (unknown), Roland Schött, Patrick Saulnier, C. Chouaïd	5
6	Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR -Mutated Advanced Non–Small Cell Lung Cancers 2017 ·Journal of Thoracic Oncology ·C. Chouaïd, (unknown), (unknown), Pascal Dô, Jaafar Bennouna, M. Pérol, Denis Moro‐Sibilot, A. Vergnenègre, Gérard de Pouvourville	30
7	Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer 2014 ·Clinical Cancer Research ·Miguel Ángel Molina‐Vila, Jordi Bertrán-Alamillo, Amaya Gascó, Clara Mayo‐de‐las‐Casas, (unknown), (unknown), Laura Bonanno, Adolfo Favaretto, Andrés F. Cardona, A. Vergnenègre, Margarita Majem, Bartomeu Massutí, Teresa Morán, Enric Carcereny, Santiago Viteri, Rafael Rosell	125
8	Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer 2012 ·Journal of Clinical Oncology ·M. Pérol, C. Chouaïd, David Pérol, Fabrice Barlési, Radj Gervais, Virginie Westeel, Jacky Créquit, H. Léna, A. Vergnenègre, Gérard Zalcman, I. Monnet, H. Le Caer, P. Fournel, L. Falchero, M. Poudenx, F. Vaylet, Céline Ségura‐Ferlay, Mojgan Devouassoux‐Shisheboran, Miquel Tarón, B. Milleron	166
9	PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: A Markov Model 2011 ·Value in Health ·Isabelle Borget, A. Vergnenègre, C. Chouaïd	0
10	PCN94 HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN 1ST LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN A REAL LIFE SETTING: BEVACIZUMAB-BASED VERSUS NON-BEVACIZUMAB BASED THERAPY IN A EUROPEAN PILOT STUDY 2011 ·Value in Health ·C. Chouaïd, (unknown), A. Vergnenègre, David F. Heigener, Gavin Taylor‐Stokes, Adam Roughley, Stefan Walzer	1
11	PCN79 Cost Effectiveness of Erlotinib in First Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC) in Vulnerable Elderly Patients: An Economical Analysis of a prospective Phase 2 Study (GFPC 0505) 2011 ·Value in Health ·C. Chouaïd, H. Le Caer, R. Corre, Jacky Créquit, (unknown), L. Falchero, (unknown), A. Vergnenègre	1
12	An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer 2011 ·Current Medical Research and Opinion ·Mark Nuijten, (unknown), Javier de Castro, A. Vergnenègre, C. Chouaïd, Stefan Walzer, Uwe Siebert	3
13	Biomarkers in lung oncology 2010 ·Pulmonary Pharmacology & Therapeutics ·Rafael Rosell, A. Vergnenègre, Baorui Liu, Manuel Cobo, Bartomeu Massutí, Jia Wei, Miguel Ángel Molina‐Vila, Carlota Costa, Cristina Queralt, Miquel Tarón	14
14	Bronchite chronique : prévalence et qualité de vie 2009 ·Revue des Maladies Respiratoires ·C. Fuhrman, Nicolás Roche, A. Vergnenègre, C. Chouaïd, Mahmoud Zureik, Marie-Christine Delmas	10
15	Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95–01) 2006 ·Annals of Oncology ·A. Vergnenègre, Christophe Combescure, P. Fournel, S. Bayle, (unknown), P.-J. Souquet, H. Léna, M. Pérol, J. Y. Delhoume	11
16	Qu’est-ce qu’une régression logistique ? 2005 ·Revue des Maladies Respiratoires ·Pierre‐Marie Preux, Peter Odermatt, (unknown), Benôıt Marin, A. Vergnenègre	15
17	L’analyse coût-efficacité : un guide de lecture 2004 ·Revue des Maladies Respiratoires ·A. Vergnenègre	6
18	[Radon and domestic exposure]. 2000 ·PubMed ·B. Melloni, A. Vergnenègre, Philippe Lagrange, F Bonnaud	14
19	Antioxidant Activity in Bronchoalveolar Lavage Fluid From Patients With Lung Cancer 1996 ·American Journal of Respiratory and Critical Care Medicine ·B. Melloni, Marc Lefebvre, F Bonnaud, A. Vergnenègre, Laurent Grossin, (unknown), André M. Cantin	31
20	[Impact on the quality of life of respiratory symptoms and airway obstruction in an agricultural population]. 1995 ·PubMed ·A. Vergnenègre, James G. Martin, (unknown), (unknown), B. Melloni, (unknown), (unknown), F Bonnaud	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact